Surgical wound complications after heart transplantation

Transplant International

Volumn 24, Issue 7, 2011, Pages 627-636

  Zuckermann, Andreas ^a   Barten, Markus J ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Heart transplantation; Immunosuppression; Mammalian target of rapamycin inhibitor; Surgical wound complication; Wound healing event

Indexed keywords

AZATHIOPRINE; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

BODY MASS; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEBRIDEMENT; DIABETES MELLITUS; HEART SURGERY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; INTERNAL MAMMARY ARTERY; MEDIASTINITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REOPERATION; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SURGICAL INFECTION; SURGICAL RISK; SURGICAL WOUND; WOUND COMPLICATION; WOUND DEHISCENCE;

CARDIAC SURGICAL PROCEDURES; DEBRIDEMENT; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MEDIASTINITIS; OBESITY; OSTEOMYELITIS; RISK FACTORS; SURGICAL WOUND INFECTION; TOR SERINE-THREONINE KINASES; WOUND HEALING;

EID: 79959830895     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01247.x     Document Type: Review

References (67)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report - 2010. J Heart Lung Transplant 2010; 29: 1089.
2. Athanassiadi KA. Infections of the mediastinum. Thorac Surg Clin 2009; 19: 37.
3. Mauermann WJ, Sampathkumar P, Thompson RL. Sternal wound infections. Best Pract Res Clin Anaesthesiol 2008; 22: 423.
4. Lepelletier D, Perron S, Bizouarn P, et al. Surgical-site infection after cardiac surgery: incidence, microbiology, and risk factors. Infect Control Hosp Epidemiol 2005; 26: 466.
5. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 2006; 6: 92.
6. Zucker MJ, Baran DA, Arroyo LH, et al. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis. Transplant Proc 2005; 37: 2231.
7. Zakliczynski M, Nozynski J, Kocher A, et al. Surgical wound-healing complications in heart transplant recipients treated with rapamycin. Wound Repair Regen 2007; 15: 316.
8. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309.
9. Molina JE, Lew RS, Hyland KJ. Postoperative sternal dehiscence in obese patients: incidence and prevention. Ann Thorac Surg 2004; 78: 912.
10. Salehi OA, Karimi A, Ahmadi SH, et al. Superficial and deep sternal wound infection after more than 9000 coronary artery bypass graft (CABG): incidence, risk factors and mortality. BMC Infect Dis 2007; 7: 112.
11. Ridderstolpe L, Gill H, Granfeldt H, Ahlfeldt H, Rutberg H. Superficial and deep sternal wound complications: incidence, risk factors and mortality. Eur J Cardiothoracic Surg 2001; 20: 1168.
12. Bouza E, Hortal J, Munoz P, et al. Infections following major heart surgery in European intensive care units: there is room for improvement (ESGNI 007 Study). J Hosp Infect 2006; 63: 399.
13. Paul M, Raz A, Leibovici L, Madar H, Holinger R, Rubinovitch B. Sternal wound infection after coronary artery bypass graft surgery: validation of existing risk scores. J Thorac Cardiovasc Surg 2007; 133: 397.
14. Centofanti P, Savia F, La Torre M, et al. A prospective study of prevalence of 60-days postoperative wound infections after cardiac surgery. An updated risk factor analysis. J Cardiovasc Surg 2007; 48: 641.
15. Jonkers D, Elenbaas T, Terporten P, Nieman F, Stobberingh E. Prevalence of 90-days postoperative wound infections after cardiac surgery. Eur J Cardiothoracic Surg 2003; 23: 97.
16. Sakamoto H, Fukuda I, Oosaka M, Nakata H. Risk factors and treatment of deep sternal wound infection after cardiac operation. Ann Thorac Cardiovasc Surg 2003; 9: 226.
17. Lucet JC, Parisian Mediastinitis Study Group. Surgical site infection after cardiac surgery: a simplified surveillance method. Infect Control Hosp Epidemiol 2006; 27: 1393.
18. Schimmer C, Reents W, Berneder S, et al. Prevention of sternal dehiscence and infection in high-risk patients: a prospective randomized multicenter trial. Ann Thorac Surg 2008; 86: 1897.
19. Zeitani J, Bertoldo F, Bassano C, et al. Superficial wound dehiscence after median sternotomy: surgical treatment versus secondary wound healing. Ann Thorac Surg 2004; 77: 672.
20. Gummert JF, Barten MJ, Hans C, et al. Mediastinitis and cardiac surgery - an updated risk factor analysis in 10,373 consecutive adult patients. Thorac Cardiovasc Surg 2002; 50: 87.
21. Carrier M, Perrault LP, Pellerin M, et al. Sternal wound infection after heart transplantation: incidence and results with aggressive surgical treatment. Ann Thorac Surg 2001; 72: 719.
22. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6: 1377.
23. Abid Q, Nkere UU, Hasan A, et al. Mediastinitis in heart and lung transplantation: 15 years experience. Ann Thorac Surg 2003; 75: 1565.
24. Senechal M, LePrince P, Tezenas du MS, et al. Bacterial mediastinitis after heart transplantation: clinical presentation, risk factors and treatment. J Heart Lung Transplant 2004; 23: 165.
25. Filsoufi F, Rahmanian PB, Castillo JG, Pinney S, Broumand SR, Adams DH. Incidence, treatment strategies and outcome of deep sternal wound infection after orthotopic heart transplantation. J Heart Lung Transplant 2007; 26: 1084.
26. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110: 2694.
27. Bouzas-Mosquera A, Crespo-Leiro MG, Paniagua MJ, et al. Adverse effects of mammalian target of rapamycin inhibitors during the postoperative period after cardiac transplantation. Transplant Proc 2008; 40: 3027.
28. Ramos A, Asensio A, Munez E, et al. Incisional surgical infection in heart transplantation. Transpl Infect Dis 2008; 10: 298.
29. Chou NK, Wang JL, Chi NH, et al. Surgical treatment of mediastinitis after cardiac transplantation. Transplant Proc 2008; 40: 2629.
30. Kohli M, Yuan L, Escobar M, et al. A risk index for sternal surgical wound infection after cardiovascular surgery. Infect Control Hosp Epidemiol 2003; 24: 17.
31. Borger MA, Rao V, Weisel RD, et al. Deep sternal wound infection: risk factors and outcomes. Ann Thorac Surg 1998; 65: 1050.
32. Tang GH, Maganti M, Weisel RD, Borger MA. Prevention and management of deep sternal wound infection. Semin Thorac Cardiovasc Surg 2004; 16: 62.
33. Toumpoulis IK, Anagnostopoulos CE, DeRose JJ, Swistel DG. The impact of deep sternal wound infection on long-term survival after coronary artery bypass grafting. Chest 2005; 127: 464.
34. Diez C, Koch D, Kuss O, Silber RE, Friedrich I, Boergermann J. Risk factors for mediastinitis after cardiac surgery - a retrospective analysis of 1700 patients. J Cardiothorac Surg 2007; 2: 23.
35. Olsen MA, Lock-Buckley P, Hopkins D, Polish LB, Sundt TM, Fraser VJ. The risk factors for deep and superficial chest surgical-site infections after coronary artery bypass graft surgery are different. J Thorac Cardiovasc Surg 2002; 124: 136.
36. Barten MJ, Arizon JM, Dong G, et al. BMI is an independent risk factor for surgical wound complication in de-novo heart transplant recipients (HTxR) regardless of the immunosuppressive therapy [abstract]. J Heart Lung Transplant 2010; 29: 270.
37. Eckhauser AE, Melvin WV, Sharp KW. Management of general surgical problems in patients with left ventricular assist devices. Am Surgeon 2006; 72: 158.
38. Humar A, Ramcharan T, Denny R, Gillingham KJ, Payne WD, Matas AJ. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation 2001; 72: 1920.
39. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998; 11: 277.
40. Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant 2007; 21: 460.
41. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002; 16: 771.
42. Mills RE, Taylor KR, Podshivalova K, Mckay DB, Jameson JM. Defects in skin gamma delta T cell function contribute to delayed wound repair in rapamycin-treated mice. J Immunol 2008; 181: 3974.
43. Ekici Y, Emiroglu R, Ozdemir H, Aldemir D, Karakayali H, Haberal M. Effect of rapamycin on wound healing: an experimental study. Transplant Proc 2007; 39: 1201.
44. van der Vliet JA, Willems MC, de Man BM, Lomme RM, Hendriks T. Everolimus interferes with healing of experimental intestinal anastomoses. Transplantation 2006; 82: 1477.
45. Willems MC, van der Vliet JA, de Man BM, van der Laak JA, Lomme RM, Hendriks T. Persistent effects of everolimus on strength of experimental wounds in intestine and fascia. Wound Repair Regen 2010; 18: 98.
46. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36.
47. Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressants - new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006; 28: 39.
48. Serkova N, Jacobsen W, Niemann CU, et al. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol 2001; 133: 875.
49. Serkova NJ, Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants - NMR-based quantitative metabonomics of the blood. Ther Drug Monit 2005; 27: 733.
50. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 1128.
51. Ekberg H, Bernasconi C, Noldeke J, et al. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004.
52. Tedesco SH Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10: 1401.
53. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555.
54. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidneytransplant recipients. Transplantation 2003; 76: 1729.
55. Grim SA, Slover CM, Sankary H, Oberholzer J, Benedetti E, Clark NM. Risk factors for wound healing complications in sirolimus-treated renal transplant recipients. Transplant Proc 2006; 38: 3520.
56. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
57. Lehmkuhl HB, Arizon J, Vigano M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation 2009; 88: 115.
58. Meiser B, Reichert B, Adamidis I, Uberfuhr P, Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005; 5: 827.
59. Barten MJ, Arizon JM, Dong G, et al. Analysis of risk factors for surgical wound complications in 1007 heart transplant recipients (HTxR) treated with three different immunosuppressive regimens [abstract]. Am J Transplant 2010; 10: 92.
60. Moro JA, Almenar L, Martinez-Dolz L, Sanchez-Lazaro I, Aguero J, Salvador A. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 2008; 40: 3034.
61. Bernabeu-Wittel M, Cisneros J, Rodriguez-Henandez MJ, Martinez A, Ordonez A, Martinez M. Suppurative mediastinitis after heart transplantation: early diagnosis with CT-guided needle aspiration. J Heart Lung Transplant 2000; 19: 512.
62. Agarwal JP, Ogilvie M, Wu LC, et al. Vacuum-assisted closure for sternal wounds: a first-line therapeutic management approach. Plast Reconstr Surg 2005; 116: 1035.
63. Fleck T, Moidl R, Grimm M, Wolner E, Zuckermann A. Vacuum assisted closure therapy for the treatment of sternal wound infections after heart transplantation: preliminary results. Zentralbl Chir 2007; 132: 138.
64. Zuckermann A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008; 27: 141.
65. Manito N, Delgado JF, Crespo-Leiro MG, et al. Clinical recommendations for the use of everolimus in heart transplantation. Transplant Rev 2010; 24: 129.
66. Pascual J, Galeano C, Celemin D, et al. Uneventful thoracic healing with everolimus after aortic valve replacement. Ann Thorac Surg 2007; 84: 271.
67. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009; 88: 69.